Omeros Corporation (FRA:3O8)

Market Cap	661.26M
Revenue (ttm)	n/a
Net Income (ttm)	-103.26M
Shares Out	n/a
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	23.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	555
Open	8.80
Previous Close	8.97
Day's Range	8.80 - 9.17
52-Week Range	2.49 - 12.39
Beta	n/a
RSI	69.32
Earnings Date	Mar 31, 2026

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 202
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3O8

Financial Performance

Financial numbers in USD